Published in Thorax on January 01, 1995
Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax (1996) 1.51
New perspectives on inhaled drug delivery and systemic bioactivity. Thorax (1995) 1.43
Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax (1997) 1.39
Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med (2010) 0.87
Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics. Br J Clin Pharmacol (2005) 0.77
Risk of severe life threatening asthma. Thorax (1996) 0.75
Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers. Br J Clin Pharmacol (1995) 0.75
The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med (1992) 8.53
Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet (1989) 5.82
Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax (1991) 3.39
Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax (1990) 3.02
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet (1990) 2.52
Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol (1989) 2.06
Cloning and expression of cDNA encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A (1984) 1.89
In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline. Br J Clin Pharmacol (1986) 1.73
Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol (1987) 1.57
Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med (1992) 1.51
Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax (1993) 1.51
Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen. J Clin Invest (1985) 1.39
Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis (1989) 1.20
Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease. Br Heart J (1985) 1.18
Beta-adrenoceptor subtypes in human, rat, guinea pig, and rabbit atria. J Cardiovasc Pharmacol (1985) 1.15
Risks versus benefits of inhaled beta 2-agonists in the management of asthma. Drug Saf (1992) 1.11
Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on beta-adrenoceptors in guinea-pig trachea. Eur J Pharmacol (1978) 1.04
Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol. Eur J Clin Pharmacol (1990) 1.03
Reproducibility of cardiac output measurement by cross sectional and Doppler echocardiography. Br Heart J (1988) 0.99
The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma. Clin Pharmacol Ther (1990) 0.96
Radioimmunological determination of fenoterol. Part II: Antiserum and tracer for the determination of fenoterol. Arzneimittelforschung (1990) 0.93
Effects of the beta 2-adrenoceptor agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium. Klin Wochenschr (1985) 0.88
Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med (1989) 0.85
Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma. Chest (1994) 0.79
Cutaneous wound healing. N Engl J Med (1999) 19.12
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (2001) 8.89
Echocardiography in chronic heart failure in the community. Q J Med (1993) 7.64
Primary non-compliance with prescribed medication in primary care. BMJ (1993) 6.80
Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: translocation during activation. J Cell Biol (1983) 5.73
Granulocyte chemotaxis: an improved in vitro assay employing 51 Cr-labeled granulocytes. J Immunol (1973) 4.61
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
Association of road-traffic accidents with benzodiazepine use. Lancet (1998) 4.01
Defective granulocyte chemotaxis in the Chediak-Higashi syndrome. J Clin Invest (1971) 3.58
Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci U S A (1999) 3.21
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science (1990) 3.15
The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol (1977) 3.13
Angiogenesis in wound healing. J Investig Dermatol Symp Proc (2000) 3.12
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
Controlled trial of an audit facilitator in diagnosis and treatment of childhood asthma in general practice. BMJ (1995) 2.77
Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system. J Exp Med (1975) 2.56
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
Controlled trial of propranolol in thyrotoxicosis. Lancet (1969) 2.54
Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ (1996) 2.51
Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase. Proc Natl Acad Sci U S A (1989) 2.49
The selective eosinophil chemotactic activity of histamine. J Exp Med (1975) 2.45
Iodination by human polymorphonuclear leukocytes: a re-evaluation. J Lab Clin Med (1977) 2.45
Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ (1997) 2.39
Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. J Clin Invest (1991) 2.38
Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A (2001) 2.35
Fibronectin fragment(s) are chemotactic for human peripheral blood monocytes. J Immunol (1982) 2.29
Peroxidase-H2O2-halide system: Cytotoxic effect on mammalian tumor cells. Blood (1975) 2.25
Introducing a drug formulary to general practice--effects on practice prescribing costs. J R Coll Gen Pract (1987) 2.24
Two cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease. Science (1988) 2.21
What determines levels of passive smoking in children with asthma? Thorax (1997) 2.20
Respiratory medicine: fighting for survival. BMJ (1992) 2.15
Wound repair in the context of extracellular matrix. Curr Opin Cell Biol (1994) 2.14
Temporal relationships of F-actin bundle formation, collagen and fibronectin matrix assembly, and fibronectin receptor expression to wound contraction. J Cell Biol (1990) 2.12
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol (1982) 2.10
Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol (1989) 2.06
Does passive smoking increase the frequency of health service contacts in children with asthma? Thorax (2001) 2.04
Treatment of ventricular arrhythmias with mexiletine (Kö 1173). Lancet (1973) 2.04
Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med (1998) 2.01
In vivo co-distribution of fibronectin and actin fibers in granulation tissue: immunofluorescence and electron microscope studies of the fibronexus at the myofibroblast surface. J Cell Biol (1984) 1.99
Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun (1982) 1.99
Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut (1997) 1.98
Studies on the mechanism of antibody-dependent polymorphonuclear leukocyte-mediated cytotoxicity. J Immunol (1977) 1.98
Clinical and epidemiologic features of infection with Mycobacterium genavense. Swiss HIV Cohort Study. Arch Intern Med (1995) 1.95
Observations on the structure, process and clinical outcomes of asthma care in general practice. Br J Gen Pract (1996) 1.94
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
A double-blind placebo-controlled trial of theophylline in general practice. Br J Clin Pract (1991) 1.93
Assembly of the neutrophil respiratory burst oxidase. Protein kinase C promotes cytoskeletal and membrane association of cytosolic oxidase components. J Biol Chem (1991) 1.92
The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood (1980) 1.91
Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro. J Clin Invest (1980) 1.89
Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Eur J Clin Pharmacol (1989) 1.88
Cutaneous tissue repair: basic biologic considerations. I. J Am Acad Dermatol (1985) 1.86
Is maintenance digoxin necessary in patients with sinus rhythm? Lancet (1979) 1.86
Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med (1994) 1.86
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Relationships between the rate of synthesis of ATP and the concentrations of reactants and products of ATP hydrolysis in maize root tips, determined by 31P nuclear magnetic resonance. Arch Biochem Biophys (1985) 1.78
C-reactive protein. A clinical marker in community-acquired pneumonia. Chest (1995) 1.77
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Role of the myeloperoxidase-H2O2-halide system in concanavalin A-induced tumor cell killing by human neutrophils. J Immunol (1979) 1.77
Characterization of an IgA rheumatoid factor: finding properties and reactivity with the subclasses of human G globulin. Immunochemistry (1972) 1.73
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol (1985) 1.72
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Calreticulin functions as a molecular chaperone in the biosynthesis of myeloperoxidase. J Biol Chem (1995) 1.69
Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix. J Cell Sci (1997) 1.67
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
An epidemiological study of digoxin prescribing in general practice. J R Coll Gen Pract (1986) 1.66
NADPH oxidase of human neutrophils. Subcellular localization and characterization of an arachidonate-activatable superoxide-generating system. J Biol Chem (1987) 1.66
Simultaneous measurement of cardiac output and its distribution with microspheres in the rat. Cardiovasc Res (1976) 1.66
Myeloperoxidase-catalyzed inactivation of alpha 1-protease inhibitor by human neutrophils. J Biol Chem (1981) 1.65
Preoperative evaluation of patients for liver resection. Appropriate CT imaging. Ann Surg (1993) 1.65
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Propranolol and the utilization of radioiodine by the human thyroid gland. Acta Endocrinol (Copenh) (1969) 1.63
Treatment of pulmonary aspergilloma with itraconazole. Thorax (1991) 1.63
Plasma binding and the affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther (1976) 1.62
Infective endocarditis: a survey of cases in the South-East region of Scotland, 1969-72. Thorax (1976) 1.59
Advising parents of asthmatic children on passive smoking: randomised controlled trial. BMJ (1999) 1.57
Defect in neutrophil granulocyte chemotaxis in Job's syndrome of recurrent "cold" staphylococcal abscesses. Lancet (1974) 1.56
Hemolysis and iodination of erythrocyte components by a myeloperoxidase-mediated system. Blood (1975) 1.56
Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol (1987) 1.55
Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax (1993) 1.51
beta-Adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol (1978) 1.50
Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. Br J Clin Pharmacol (1989) 1.48
Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax (1997) 1.48
The myeloperoxidase-hydrogen peroxide-halide system as effector of neutrophil-mediated tumor cell cytotoxicity. J Immunol (1981) 1.47
Plasma digoxin concentrations in patients on admission to hospital. Br Heart J (1974) 1.46
Myeloperoxidase--H2O2--halide system: cytotoxic effect on human blood leukocytes. Blood (1977) 1.45
Contribution of the vagus to the haemodynamic responses following intravenous boluses of isoprenaline. Br J Clin Pharmacol (1983) 1.44
Adverse reactions and interactions with beta-adrenoceptor blocking drugs. Med Toxicol (1987) 1.44
Fibronectin in delayed-type hypersensitivity skin reactions: associations with vessel permeability and endothelial cell activation. J Immunol (1981) 1.42
Defective neutrophil chemotaxis and cellular immunity in a child with recurrent infections. Ann Intern Med (1973) 1.42
Redistribution of intracellular Ca2+ stores during phagocytosis in human neutrophils. Science (1994) 1.39
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol (1989) 1.39
Screening mammography in the Tampa Bay area: current status and implications for the next decade. J Fla Med Assoc (1989) 1.39
Chemotactic factor inactivation by the myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest (1979) 1.39
Interactive effects of salinity and phosphorus nutrition of the concentrations of phosphate and phosphate esters in mature photosynthesizing corn leaves. Plant Physiol (1976) 1.39
Digoxin compliance in patients from general practice. Br J Clin Pharmacol (1978) 1.38